HCW Biologics (HCWB) shares more than doubled amid heavy trading after the company said Monday that it received US Food and Drug Administration clearance to launch a phase 1 trial to evaluate HCW9302 for treating moderate-to-severe alopecia areata.
Over 313.9 million shares traded intraday versus a daily average of roughly 9.9 million.
GH Research (GHRS) said Monday that a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.
Shares surged 82% as intraday trading volume catapulted to over 8.4 million from a daily average of about 79,000.
Triumph Group (TGI) said Monday that it agreed to be acquired and taken private by the affiliates of Warburg Pincus and Berkshire Partners in a roughly $3 billion all-cash deal.
Shares of the aerospace supplier jumped 34%, with intraday trading volume rising to over 14.4 million compared with a daily average of about 699,000.
Price: 0.66, Change: +0.39, Percent Change: +138.75
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。